(HealthDay)—Clinical guidelines on adjuvant and salvage radiotherapy after radical prostatectomy have been updated, according to the American Society for Radiation Oncology and the American ...

No clear consensus guidelines exist for managing biochemically recurrent prostate cancer (PCa) after radical prostatectomy (RP), but evidence suggests salvage radiotherapy (SRT) is a viable option ...

Adjuvant and Salvage Radiotherapy After Prostatectomy:ASTRO/AUA Guideline Amendment Executive Summary 2018. Practical Radiation Oncology, 2019; DOI: 10.1016/j.prro.2019.04.008; ...

The Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline (available online in the Journal of Urology and in Practical Radiation Oncology was amended as follows: ...

Similarly, late grade 2 or worse genitourinary toxicities were documented in 27% of patients in the adjuvant radiotherapy group, vs 7% of those in the salvage radiotherapy group (P < .0001).

The American Urological Association released a clinical practice guideline pertaining to salvage therapy for men with prostate cancer.The guideline, issued in collaboration with American Society ...

LINTHICUM, Md. and ARLINGTON, Va., April 30, 2019 /PRNewswire/ -- The American Society for Radiation Oncology (ASTRO) and the American Urological ...

Current guidelines recommend all men be offered hormone therapy when receiving salvage radiotherapy (SRT) following prostate cancer surgery and subsequent biochemical recurrence.

Yet still, it was the first study to show that ADT could benefit patients undergoing salvage radiation, he said. Findings from SPPORT, which were presented at last year's ASTRO meeting and tested ...

Recurrent disease following primary radiotherapy for localized prostate cancer is a common problem, occurring in up to 46% of patients. For these patients, therapeutic options include salvage ...

June 18 -- TUESDAY, June 17 (HealthDay News) -- Countering common medical theory, a new study finds that radiation therapy may save the lives of many men whose prostate cancer recurs aggressively ...